RNS2 Aug 2018 08:44
Main extract but not all.
£6.41m Placing with Swiss based Investors & Healthcare Providers
Advanced Oncotherapy (AIM: AVO), the developer of next-generation proton therapy systems for cancer treatment, announces that it has successfully raised £6.41m (before expenses) through the issue of 13,086,859 new ordinary shares of 25 pence each ("Ordinary Shares") in the capital of the Company at a price of 49 pence per share to a number of new investors based in Switzerland and certain directors of the Company (the "Placing").
The Placing, undertaken by Geneva based Synergy Wealth Management SA, has attracted a number of prominent Swiss Private Banks, including healthcare providers based in Switzerland participating in the Placing alongside them.
The funds will be used for general working capital purposes as the Company continues the development of its first LIGHT system, for software development and costs relating to the new testing and assembly site being installed at the UK Government's Science and Technology Facilities Council at Daresbury. The additional funding will also be used for development extending beyond the key milestone of creating a beam capable of treating superficial tumours, which remains on track to be completed by the end of Q3 this year.